edaravone / Generic mfg. - LARVOL DELTA

Gland Pharma receives USFDA approval for Edaravone Injection (ExpressPharma) - "Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL), Single-Dose Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Radicava Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL) of Mitsubishi Tanabe Pharma Corporation. The Product is used to treat amyotrophic lateral sclerosis (ALS), a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken. The Company expects to launch this Product through its marketing partner within FY25. According to IQVIA, the product had US sales of approximately USD 19 million for the twelve months ending January 2024."

ANDA • Generic launch • Sales • Amyotrophic Lateral Sclerosis • CNS Disorders

A Study on the Association between Korotkoff Sound Signaling and Chronic Heart Failure (CHF) Based on Computer-Assisted Diagnoses. (PubMed, J Healthc Eng) - "The ALSAVA maneuver indicated that the KS signal could play an important role in the diagnosis of CHF...In the measured data set, our method performed well in terms of classification accuracy, sensitivity, and specificity. In light of this, we believed that the methods described in this paper can be applied to the early, noninvasive detection of heart disease as well as a supplementary monitoring technique for the prognosis of patients with CHF."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Iranian-made ALS medicine saves $42,000 per patient annually (Tehran Times) - “The Iranian-made medicine for amyotrophic lateral sclerosis (ALS), called Alsava, will reduce treatment costs from currently $47,000 to $5,000 per patient annually, IRNA reported. The first Iranian-made medicine was unveiled during a ceremony in Tehran on Sunday.”

HEOR